BIOA-B.ST

BioArctic AB (publ) [BIOA-B.ST] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

BIOA-B.ST Stock Summary

Earnings have grown 169.83% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

EPS has increased from the previous year and become positive (Yearly statements)

BIOA-B.ST has more than 3 years of cash runway (38 months)

Earnings are expected to fall -100% next year

Top 10 Correlated ETFs

BIOA-B.ST

Top 10 Correlated Stocks

BIOA-B.ST

In the News

BIOA-B.ST Financial details

Company Rating

Sell

Market Cap

17.48B

Income

229.25M

Revenue

615.99M

Book val./share

11.85

Cash/share

6.93

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

17 May 2024

P/E

93.86

Forward P/E

PEG

-0.45

P/S

39.2

P/B

21.5

P/C

28.43

P/FCF

191.82

Quick Ratio

6.21

Current Ratio

10.81

Debt / Equity

LT Debt / Equity

EPS (TTM)

2.6

EPS next Y

EPS next Q

EPS this Y

-2100%

EPS next Y

EPS next 5Y

EPS last 5Y

21.06%

Revenue last 5Y

16.93%

Revenue Q/Q

-94.72%

EPS Q/Q

-169.72%

SMA20

-10.92%

SMA50

-8.11%

SMA100

-10.92%

Inst Own

Inst Trans

ROA

21%

ROE

26%

ROC

0.24%

Gross Margin

88%

Oper. Margin

44%

Profit Margin

43%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

191.5-392.0

52W High

-49.74%

52W Low

+3.14%

RSI

Rel Volume

1.09

Avg Volume

134.63K

Volume

146.9K

Perf Week

-5.29%

Perf Month

-7.51%

Perf Quarter

-17.44%

Perf Half Y

-21.95%

Beta

-0.17

Volatility

5.25%, 11.99%

Prev Close

-3.34%

Price

197

Change

-1.6%

BIOA-B.ST Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	3.2	0.71	0.26	2.59	6.99
Net income per share	1	-0.78	-1.36	-0.13	2.6
Operating cash flow per share	3.72	-1.05	-1.6	-0.36	3.39
Free cash flow per share	3.68	-1.19	-1.64	-0.5	3.39
Cash per share	12.64	11.36	9.63	9.14	6.94
Book value per share	11.07	10.3	8.96	8.93	11.87
Tangible book value per share	11.07	10.3	8.96	8.93	11.87
Share holders equity per share	11.07	10.3	8.96	8.93	11.87
Interest debt per share	0.32	0.25	0.19	0.12	0.15
Market cap	8.36B	8.4B	10.5B	23.96B	23.61B
Enterprise value	7.27B	7.42B	9.66B	23.16B	23.01B
P/E ratio	94.46	-122.61	-87.63	-2.14K	103
Price to sales ratio	29.66	134.74	453.5	104.94	38.33
POCF ratio	25.54	-90.98	-74.73	-757.2	78.96
PFCF ratio	25.8	-80.15	-72.47	-539.75	78.96
P/B Ratio	8.58	9.26	13.31	30.47	22.56
PTB ratio	8.58	9.26	13.31	30.47	22.56
EV to sales	25.81	119.04	417.53	101.45	37.35
Enterprise value over EBITDA	58.94	-99.79	-76.36	5.75K	83.62
EV to operating cash flow	22.23	-80.37	-68.81	-732.06	76.94
EV to free cash flow	22.45	-70.81	-66.72	-521.83	76.94
Earnings yield	0.01	-0.01	-0.01	0	0.01
Free cash flow yield	0.04	-0.01	-0.01	0	0.01
Debt to equity	0.03	0.02	0.02	0.01	0
Debt to assets	0.02	0.02	0.02	0.01	0
Net debt to EBITDA	-8.8	13.17	6.58	-197.6	-2.2
Current ratio	7.67	9.27	8.51	11.58	9.22
Interest coverage	94.41	-74.97	-166.73	-18.17	24.72
Income quality	2.91	1.09	1.01	1.81	1.3
Dividend Yield	0.02	0	0	0	0
Payout ratio	1.49	0	0	0	0
Sales general and administrative to revenue	0.11	0.37	1.07	0	0
Research and developement to revenue	0.26	0.81	2.38	0.33	0.15
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	-0.01	0.14	0.03	0.4	0
Capex to revenue	-0.01	-0.2	-0.19	-0.06	0
Capex to depreciation	-0.35	-1.14	-0.34	-0.9	0
Stock based compensation to revenue	0	0.02	0.07	0.01	0
Graham number	15.82	13.43	16.56	5.05	26.35
ROIC	0.09	-0.07	-0.15	-0.01	0.2
Return on tangible assets	0.07	-0.07	-0.13	-0.01	0.19
Graham Net	10.53	9.78	8.47	8.44	5.35
Working capital	995.17M	899.64M	760.52M	749.96M	1.03B
Tangible asset value	976.01M	908.86M	790.26M	787.85M	1.05B
Net current asset value	935.55M	865.35M	752.73M	748.78M	1.01B
Invested capital	0.03	0.02	0.02	0.01	0
Average receivables	14.34M	17.14M	7.32M	8.5M	3.98M
Average payables	11.51M	11.26M	13.06M	16.65M	47.39M
Average inventory	1.47M	1.47M	0.5	3.75M	3.75M
Days sales outstanding	37.15	32.79	142.62	12.72	0
Days payables outstanding	41.42	103.97	78.33	105.54	99.2
Days of inventory on hand	14.81	0	0	36.82	0
Receivables turnover	9.82	11.13	2.56	28.69	0
Payables turnover	8.81	3.51	4.66	3.46	3.68
Inventory turnover	24.64	0	55.07M	9.91	0
ROE	0.09	-0.08	-0.15	-0.01	0.22
Capex per share	-0.04	-0.14	-0.05	-0.14	0

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.02	4.46	0.03	2.37	0.12
Net income per share	-0.66	3.33	-1.16	1.42	-0.99
Operating cash flow per share	-0.66	3.39	-0.72	-0.6	1.32
Free cash flow per share	-0.7	3.39	-0.73	-0.6	1.32
Cash per share	9.14	12.55	11.81	7.91	6.93
Book value per share	8.92	12.31	11.27	12.79	11.85
Tangible book value per share	8.92	12.31	11.27	12.79	11.85
Share holders equity per share	8.92	12.31	11.27	12.79	11.85
Interest debt per share	0.11	0.11	-0.03	0.04	0.13
Market cap	23.96B	22.16B	24.87B	24.98B	23.65B
Enterprise value	23.17B	21.06B	23.84B	24.28B	23.04B
P/E ratio	-103.5	18.85	-60.78	49.98	-67.77
Price to sales ratio	11.47K	56.33	9.19K	119.61	2.15K
POCF ratio	-411.67	74.12	-389.73	-471.91	202.52
PFCF ratio	-387.4	74.12	-384.31	-471.91	202.52
P/B Ratio	30.48	20.42	25.02	22.13	22.6
PTB ratio	30.48	20.42	25.02	22.13	22.6
EV to sales	11.08K	53.54	8.81K	116.28	2.09K
Enterprise value over EBITDA	-428.4	67.85	-247.52	166.87	-308.01
EV to operating cash flow	-398.01	70.45	-373.49	-458.79	197.33
EV to free cash flow	-374.55	70.45	-368.3	-458.79	197.33
Earnings yield	0	0.01	0	0.01	0
Free cash flow yield	0	0.01	0	0	0
Debt to equity	0.01	0.01	0.01	0	0
Debt to assets	0.01	0.01	0.01	0	0
Net debt to EBITDA	14.71	-3.54	10.76	-4.77	8.11
Current ratio	11.58	16.28	11.59	10.81	9.22
Interest coverage	1.01K	143.07	11.89	388.76	-9.36
Income quality	0.96	0.99	0.63	-0.4	-1.34
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	6.77	0.08	5.74	0.07	2.58
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.06	0	0.01	0	0
Capex to revenue	-1.74	0	-0.33	0	0
Capex to depreciation	-0.95	0	-0.2	0	0
Stock based compensation to revenue	1.32	0	0	0	0
Graham number	11.49	30.39	17.15	20.18	16.23
ROIC	-0.08	0.26	-0.11	0.1	-0.09
Return on tangible assets	-0.07	0.25	-0.09	0.1	-0.07
Graham Net	8.43	11.76	10.77	6.62	5.35
Working capital	749.96M	1.05B	964.21M	1.1B	1.03B
Tangible asset value	787.85M	1.09B	995.66M	1.13B	1.05B
Net current asset value	748.78M	1.05B	962.68M	1.1B	1.01B
Invested capital	0.01	0.01	0.01	0	0
Average receivables	3.98M	3.98M	0	0	0
Average payables	16.32M	23.93M	34.96M	51.52M	66.39M
Average inventory	3.75M	3.75M	0	0	0
Days sales outstanding	342.65	0	0	0	0
Days payables outstanding	136.78	78.74	252.39	346.21	106.08
Days of inventory on hand	47.71	0	0	0	0
Receivables turnover	0.26	0	0	0	0
Payables turnover	0.66	1.14	0.36	0.26	0.85
Inventory turnover	1.89	0	0	0	0
ROE	-0.07	0.27	-0.1	0.11	-0.08
Capex per share	-0.04	0	-0.01	0	0

BIOA-B.ST Frequently Asked Questions

What is BioArctic AB (publ) stock symbol ?

BioArctic AB (publ) is a SE stock and trading under the symbol BIOA-B.ST

What is BioArctic AB (publ) stock quote today ?

BioArctic AB (publ) stock price is $197 today.

Is BioArctic AB (publ) stock public?

Yes, BioArctic AB (publ) is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 134.63K
Market Capitalization 17.48B
Employee 88
CEO Dr. Gunilla Osswald Ph.D.
Headquarters Stockholm,SE
IPO Date 2017-10-12
Website https://www.bioarctic.se

BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.